NeOnc Technologies Reports Phase 2a Results for NEO100-01

What Happened

• On August 12, 2026, NeOnc Technologies Holdings, Inc. announced results from the Phase 2a portion of its NEO100-01 clinical program and released a related press release under Regulation FD. The company also hosted an investor conference call that day to discuss the data and provided the investor presentation used on the call.

Key Details

• Announcement date: August 12, 2026.
• Event: Press release announcing Phase 2a data for NEO100-01 (furnished as Exhibit 99.1).
• Investor materials: Presentation used on the August 12 investor call furnished as Exhibit 99.2.
• Disclosure type: Regulation FD disclosure reported on Form 8-K (Item 7.01); exhibits furnished under Item 9.01.

Why It Matters

• This filing provides investors with the company’s first public update on the Phase 2a portion of NEO100-01, a key milestone in NeOnc’s clinical development program. The press release and investor presentation are the primary documents to review for details on safety, efficacy, or next steps that could affect the company’s development timeline and investor interest.